Skip to content
Home
Our Science
Therapeutic Areas
Team & Investors
Careers
News & Resources
Connect
News &
Resources
Featured Stories
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Read More
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Read More
Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Read More
All-In Podcast
2023 All-In Summit – A discussion on the future of gene therapy
Read More
News
Patient Resources
Videos
All
Media Coverage
Press Releases
Press Releases
|
Posted on 5.17.23
Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy for Cancer
Read More
Media Coverage
|
Posted on 3.2.23
Nicole Paulk is named one of the Bay Area’s next generation of life science researchers
Read More
Media Coverage
|
Posted on 12.5.22
Insights from Nicole Paulk on the latest gene therapy for hemophilia B
Read More
Media Coverage
|
Posted on 8.25.22
Siren’s Founder & CEO, Nicole Paulk, speaks on pricing and access for gene therapies
Read More
Media Coverage
|
Posted on 10.1.21
Hear from Nicole Paulk on XLMTM gene therapy
Read More
Media Coverage
|
Posted on 8.12.21
Nicole Paulk on gene therapy’s next steps
Read More
Media Coverage
|
Posted on 5.17.21
Beyond AAV 1.0 – Nicole Paulk discusses breaking down barriers for the future of AAV
Read More
1
2
3
4